Red Light Holland (TRIP) investor relations material

Executive summary

• Revenue grew 4.05% year-over-year to $4.944M, reflecting a strategic exit from low-margin businesses and disciplined cost management.

• Adjusted EBITDA loss reduced by over 23%, with nearly all operating subsidiaries cash positive for the year.

• Maintained a strong cash balance of $12.8M, supporting ongoing investments and strategic initiatives.

• Achieved global milestones in psilocybin R&D, including the first legal shipment to a U.S. FDA/DEA-registered lab.

• Major retail wins included expanded distribution with Costco, Albertsons, and Safeway, and the launch of Health Canada-approved functional mushroom gummies.

Financial highlights

• Revenue reached $4.944M, up 4.05% year-over-year, driven by a shift to higher-margin products.

• Gross profit was $1.913M, down 5.31% from last year, reflecting product mix and cost discipline.

• Adjusted EBITDA loss improved to $2.532M from $3.3M, a 23.54% reduction.

• Cash position at year-end was $12.8M, down from $14.4M, mainly due to investments in product development and strategic initiatives.

• Total assets closed at $21.2M, down from $24.1M, due to nonrecurring adjustments and write-downs.

Outlook and guidance

• Focus remains on profitability, controlled growth, and careful capital management.

• Plans to redeploy capital from the potential sale of the Peterborough/AEM Ontario farm into higher-return opportunities, especially functional mushrooms and DTC marketing.

• Continued advocacy and R&D in psychedelics, with regulatory changes in Canada and the US closely monitored.

• Expansion of functional mushroom gummies and global retail strategies expected to drive growth.